Verrica Pharmaceuticals Inc. cash flow to debt ratio of -1.08K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Verrica Pharmaceuticals Inc.'s free cash flow has increased -71.08% from $-60.95M last year to $-17.63M, signaling increasing performance

Verrica Pharmaceuticals Inc.'s debt to equity ratio is 0.42, which means that the company's assets are healthy financed, signaling financial stability.

Verrica Pharmaceuticals Inc.'s debt has increased relative to shareholder equity from -4.66 last year to 0.42 today, signaling weakened financials

Verrica Pharmaceuticals Inc. has a net cash position, so leverage is healthy.

Verrica Pharmaceuticals Inc.'s interest coverage ratio is -7.54, which means that the company struggles to meet interest obligations, signaling financial risk.

Verrica Pharmaceuticals Inc.'s profit margin has increased (-89.84%) in the last year from -1.01K% to -102.84%, signaling increasing performance

Verrica Pharmaceuticals Inc.'s short-term assets of $42.54M exceed its short-term liabilities of $16.44M

Verrica Pharmaceuticals Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Verrica Pharmaceuticals Inc.'s return on equity of -444.44%, is lower than 15.00%, indicating bad performance

Verrica Pharmaceuticals Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Verrica Pharmaceuticals Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Verrica Pharmaceuticals Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Verrica Pharmaceuticals Inc. has negative free cash flow, indicating cash burn

Verrica Pharmaceuticals Inc.'s yearly earnings has increased -76.64% since last year from $-76.58M to $-17.89M, signaling increasing performance

Verrica Pharmaceuticals Inc.'s yearly revenue has increased 370.22% since last year from $7.57M to $35.58M, signaling increasing performance

ROIC -193.59% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Verrica Pharmaceuticals Inc.'s 3-year revenue CAGR of 57.93% is positive, indicating growing revenue over the past 3 years

Verrica Pharmaceuticals Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Verrica Pharmaceuticals Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Verrica Pharmaceuticals Inc. has insufficient data to evaluate this check.

Verrica Pharmaceuticals Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Verrica Pharmaceuticals Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Verrica Pharmaceuticals Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Verrica Pharmaceuticals Inc. has insufficient data to evaluate this check.

Verrica Pharmaceuticals Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Verrica Pharmaceuticals Inc. has a price-to-book ratio of 25.32x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Verrica Pharmaceuticals Inc. has a price-to-sales ratio of 3.60x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue